KBC Group NV Cuts Position in Elanco Animal Health Incorporated (NYSE:ELAN)

KBC Group NV decreased its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 69.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 98,674 shares of the company's stock after selling 224,828 shares during the period. KBC Group NV's holdings in Elanco Animal Health were worth $1,036,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. CoreCap Advisors LLC bought a new position in shares of Elanco Animal Health in the fourth quarter valued at about $29,000. Parallel Advisors LLC increased its stake in Elanco Animal Health by 92.2% during the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after purchasing an additional 1,852 shares in the last quarter. NBC Securities Inc. bought a new position in shares of Elanco Animal Health during the 1st quarter worth approximately $40,000. Jones Financial Companies Lllp grew its stake in shares of Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after acquiring an additional 2,059 shares in the last quarter. Finally, Versant Capital Management Inc boosted its holdings in shares of Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after buying an additional 1,740 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on ELAN. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday. Stifel Nicolaus lifted their target price on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $15.33.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN traded down $0.08 during trading on Friday, hitting $14.64. 2,007,920 shares of the company's stock were exchanged, compared to its average volume of 5,088,160. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.71 and a quick ratio of 1.46. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $15.78. The business's 50-day simple moving average is $12.93 and its 200 day simple moving average is $11.59. The company has a market cap of $7.27 billion, a price-to-earnings ratio of 19.78, a PEG ratio of 2.86 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. Elanco Animal Health's quarterly revenue was down 1.0% compared to the same quarter last year. During the same period last year, the company earned $0.34 EPS. As a group, equities analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.